Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-11-05 | New | $1,406,112 | $1,406,112 | Equity Only | 06b | SEC link |
| 2025-01-08 | Amended | $5,222,095 | $2,842,595 | Other | 06b | SEC link |
| 2025-01-08 | New | $5,184,500 | $5,184,500 | Equity Only | 06b | SEC link |
| 2023-08-03 | Amended | $2,379,500 | $225,000 | Equity Only | 06b | SEC link |
| 2023-01-11 | New | $2,154,500 | $2,154,500 | Equity Only | 06b | SEC link |
| 2021-11-04 | New | $374,993 | $374,993 | Equity Only | 06b | SEC link |
| 2021-02-09 | New | $825,000 | $825,000 | Equity Only | 04 | SEC link |
| 2019-11-14 | New | $1,490,000 | $1,490,000 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Mark Chance | Director |
| George Cox | Director |
| Jim Haymaker | Director |
| James Haymaker | Director, Promoter |
| John Hurley | Executive |
| Peter Kosa | Director |
| David Largaespada | Director, Promoter |
| Jeff Liter | Director, Executive, Promoter |
| Tracey Lodie | Director |
| Branden Moriarity | Director |
| Alexander Naydich | Director |
| Jeff Ross | Director |
| John Wells | Director |